N/A N=120 Training-induced Increased Left Ventricular Trabeculation
Athletes Heart · Left Ventricular Hypertrabeculation
Primary: Thickness of Compacted Myocardial Tissue (cm) — 0.53; 0.56; 0.8; 0.85 cm — p=0.44
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=74 Impact of a Family History of Hypertension and Physical Activity on Left Ventricular Mass
Genetic Predisposition · Genetic Hypertension
Primary: Left Ventricular Mass — 155.1680523; 129.5013331 gram
Phase 3 N=287 The CLEVER Study - Coreg And Left Ventricular Mass Regression
Hypertrophy, Left Ventricular
Primary: Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Magnetic Resonance Imaging (MRI) at Month 12…
N/A N=36 Exercise,Metabolic Syndrome and Weight Regain (Echocardiography Substudy)
Metabolic Syndrome · Obesity
Primary: Mean Resting E/E' — 7.01 ml/min/kg — p==0.14
N/A N=11 Exercise Training in Heart Failure: Changes in Cardiac Structure and Function
Heart Failure
Primary: Change in Left Ventricular Systolic Function. — .82; -1.90 percent LVEF — p=.14
N/A N=812 Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Primary: Percentage of Participants With Cardiac Fixation at the Radionuclide Bone Scintigraphy and/or Single Photon Emission Computed Tomography (SPECT): FAS1 — 32.0 Percentage…
N/A N=190 Attain Model 4196 Left Ventricular (LV) Lead
Heart Failure
Primary: Safety (Subjects Without a Model 4196 Lead Related Complication) — 168 participants
N/A N=197 Model 4396 Left Ventricular (LV) Lead Study
Heart Failure
Primary: Safety (Subjects Without a Model 4396 Lead Related Complication) — 155 participants
N/A N=14 REmodeling the Left Ventricle With Atrial Modulated Pacing
Heart Failure
Primary: Number of Participants Who Remained on Study — 9; 4 participants
Phase 2 N=46 Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy
Cardiomyopathy, Hypertrophic
Primary: Change From Baseline in Peak VO2 as Measured by Cardiopulmonary Exercise Test (CPET) — 1.00; 0.39 mL/kg/min — p=0.5506
N/A N=30 Effect of Intradialytic Exercise on Left Ventricular Diastolic Function in Hemodialysis Patients
Renal Dialysis · Hemodiafiltration · Diastolic Dysfunction
Primary: Left Ventricular Diastolic Function Category — 15; 15; 5; 5 Participants — p=0.06
Phase 3 N=72 Impact of Diabetes on Left Ventricular Remodeling
Diabetes
Primary: Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) — 73.03; 78.06; 78.52; 79.03 ml/m^2
Phase 2 N=56 Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary Trial
Heart Failure · Growth Hormone Deficiency · Ischemic Heart Disease
Primary: Peak VO2 — 14.5; 12.9 ml/kg/min
N/A N=211 Identifying and Facilitating Ventricular Recovery on Mechanical Support
Heart Failure
Primary: Number of Subjects With Left Ventricular Recovery and LVAD Explant — 8 Participants
N/A N=15 Right Ventricular Function and Exercise Capacity in Patients With Continuous-flow Left Ventricular Assist Devices
Heart Failure
Primary: Peak Oxygen Uptake — 15 ml/kg/min
N/A N=10 On-pump Intraoperative Echocardiography
Septal Myectomy
Primary: Septal Thickness Measured Before Cardiopulmonary Bypass — 22.9; 22.5 millimeters
N/A N=60 Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer
Breast Cancer
Primary: LVEF — 65.4; 64.7; 62.2 percentage of blood in left ventricle — p=<0.0005
N/A N=53 Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function
Hypertension
Primary: Resting Systolic BP — 135 mm Hg — p=<0.05
Phase 2 N=21 A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Cardiomyopathy, Hypertrophic Obstructive · Left Ventricular Outflow Tract Obstruction
Primary: Change in Post-exercise Peak LVOT Gradient From Baseline to Week 12 — -89.5; -25.0 mm Hg
Phase 3 N=93 The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI
Heart Failure
Primary: Change in Left Ventricular End Systolic Volume Index — -4.0; -2.0 ml/m^2 — p=0.19
Phase 3 N=133 PUFAs and Left Ventricular Function in Heart Failure
Dilated Cardiomyopathy · Heart Failure
Primary: Change in Left Ventricular (LV) Systolic Function Expressed as Left Ventricular Ejection Fraction (LVEF) Between Baseline and 12-month Follow-up — 36; 37; 39; 35…
Phase 4 N=56 Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart
Idiopathic Dilated Cardiomyopathy
Primary: Improvement in Left Ventricular Ejection Fraction (LVEF) at 12 Months — 12; 10; 9 LVEF responders — p=0.685
N/A N=136 Study of Exercise Training in Hypertrophic Cardiomyopathy
Cardiomyopathy, Hypertrophic
Primary: Change in Peak Oxygen Consumption (Peak VO2) — 1.35; 0.08 mL/kg/min
Phase 4 N=53 Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
Myocardial Fibrosis · Hypertrophic Cardiomyopathy
Primary: Absolute Change in Serum Markers of Collagen Turnover (Micrograms/L) Over a One-year Follow-up Period in the Spironolactone Group Compared to Placebo. — 2.1; 2.1; 0.7…
N/A N=50 The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study
Mitral Regurgitation · Pulmonary Hypertension
Primary: Impaired Post-operative Functional Capacity — 35 Participants
N/A N=111 Left Atrial Distensibility to Predict Left Ventricular Filling Pressure and Prognosis in Patients With Severe Mitral Regurgitation
Mitral Valve Insufficiency · Atrial Fibrillation · Heart Failure
Primary: Left Ventricular Filling Pressure More Than 15 mmHg Measured by Left Ventricular Catheterization — 25.5 mmHg
Phase 2 N=10 Myocardial Hemodynamic Effects of Levosimendan
Heart Failure
Primary: Change in Left Ventricular End-diastolic Pressure (LVEDP) Using Pressure-volume Catheter. — 5.67 mmHg
Phase 3 N=38 Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)
Mitral Regurgitation
Primary: Left Ventricular End Diastolic Volume Indexed to Body Surface Area — 91.66; 95.74; 90.93; NA ml/m^2 — p=0.4568
Phase 2 N=58 Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
Congestive Heart Failure
Primary: Change in Natriuresis (Urinary Sodium Excretion) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment — 87.19…
N/A N=90 Model 4296 Left Ventricular (LV) Lead Study
Heart Failure
Primary: Number of Participants With Left Ventricular (LV)Lead Related Complications — 1 participants